Click to view the official SEC document.

Click to view the official SEC document.

Cumberland Pharmaceuticals (Nasdaq: CPIX) reported Q2 2026 results alongside the closing of a $100 million Strategic Transaction with Apotex Health, plus $11 million for inventory and transition services. Apotex acquired Cumberland’s portfolio of FDA-approved brands and related commercial organization, while Cumberland retained its late-stage development pipeline and majority stake in Cumberland Emerging Technologies.The company’s board declared a $1.50 per share special cash dividend, paid July 31, 2026. Cumberland is transitioning to a development-stage biopharmaceutical model focused on four Phase 2 ifetroban programs, including Duchenne muscular dystrophy and cancer metastasis. For Q2 2026, loss from continuing operations was $3.1 million, with a total net loss of $4.1 million. As of June 30, 2026, Cumberland reported $62.9 million in total assets, $45.8 million in total liabilities, and $17.1 million in total equity, and it retired its $5.2 million bank line of credit.

Phase 2 programs are evaluating ifetroban in four diseases as Cumberland plans an Aug. 4 call to discuss results at 4:30 p.m. ET.

Click to view the official SEC document.

Record Date is July 10, 2026 & Payment Date is July 31,2026 Corporate and Insider Share Purchase Initiatives to Continue NASHVILLE, Tenn., July 13, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products...

Click to view the official SEC document.

$100 million Transaction Follows Cumberland Shareholder Approval Strengthens Cumberland's Focus on Rare Disease Pipeline. NASHVILLE, Tenn., July 1, 2026/ PRNewswire/-- Cumberland Pharmaceuticals Inc., a U.S. biopharmaceutical company, today announced the closing on an agreement with subsidiary of Apotex Health Corp., the largest Canadian-based...

Additional cardiac biomarker analyses further demonstrate ifetroban's cardioprotective effect in DMD patients NASHVILLE, Tenn., June 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-focused biopharmaceutical company committed to developing new...

Additional cardiac biomarker analyses further demonstrate ifetroban's cardioprotective effect in DMD patients. NASHVILLE, Tenn., June 26, 2026/ PRNewswire/-- Cumberland Pharmaceuticals Inc., an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, today shared updated results from its Phase 2 FIGHT DMD...

Click to view the official SEC document.

The biotech deal includes 8.6 million ADSs and two warrant series. RedHill plans to use proceeds for a potential product acquisition, R&D and working capital.

RedHill Biopharma (ticker: CPIX) announced that the FDA granted rare pediatric disease designation to opaganib for treating neuroblastoma, in addition to existing orphan drug designation.Benefits may include a Priority Review Voucher, potential seven years' marketing exclusivity, fee waivers, tax credits and accelerated review, if approved.

A $10.9M New York court judgment for RedHill is now in enforcement proceedings in Korea, with asset attachment in place and recovery timing still uncertain.

Cumberland Pharmaceuticals (Nasdaq:CPIX)/b) and reported positive Phase 2a data for ifetroban in patients with high-risk solid tumors. The trial met its primary endpoint, showing safety and tolerability, and delivered encouraging secondary signals in distant metastatic recurrence and deaths due to metastatic disease, supporting further development.

RedHill Biopharma (NASDAQ:CPIX) is pursuing collaborations, including with the WHO SOLIDARITY CORE platform, to clinically evaluate opaganib as a potential Ebola virus disease (EVD) treatment, targeting the Bundibugyo ebolavirus subtype.According to RedHill, opaganib has Phase 3 antiviral data in severe COVID-19 and preclinical Ebola activity, but remains investigational and unapproved.

Cumberland Pharmaceuticals (Nasdaq: CPIX) announced the launch of Vibativ (telavancin) injection in China through an exclusive commercialization partnership with SciClone Pharmaceuticals, following NMPA regulatory approval.Vibativ is a once-daily, patented, FDA-approved antibiotic for serious Gram-positive infections, including MRSA-related hospital-acquired and ventilator-associated pneumonia and complicated skin and skin structure infections.

Enters into Strategic Transaction, unlocking $100 million in value Sharpens focus on Orphan Drug candidates to address unmet medical needs NASHVILLE, Tenn., May 5, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that...